The onset of inflammation is associated with reactive oxygen species and oxidative damage to macromolecules like 7,8-dihydro-8-oxoguanine (8-oxoG) in DNA. Because 8-oxoguanine DNA glycosylase 1 (OGG1) binds 8-oxoG and because Ogg1-deficient mice are resistant to acute and systemic inflammation, we hypothesized that OGG1 inhibition may represent a strategy for the prevention and treatment of inflammation. We developed TH5487, a selective active-site inhibitor of OGG1, which hampers OGG1 binding to and repair of 8-oxoG and which is well tolerated by mice. TH5487 prevents tumor necrosis factor-a-induced OGG1-DNA interactions at guanine-rich promoters of proinflammatory genes. This, in turn, decreases DNA occupancy of nuclear factor kB and proinflammatory gene expression, resulting in decreased immune cell recruitment to mouse lungs. Thus, we present a proof of concept that targeting oxidative DNA repair can alleviate inflammatory conditions in vivo.
U pon exposure to proinflammatory agents, cells produce increased levels of reactive oxygen species (ROS), which induce oxidative DNA damage. Guanine is particularly vulnerable because it has the lowest oxidation potential among canonical DNA bases (1, 2) , resulting primarily in 7,8-dihydro-8-oxoguanine (8-oxoG) , particularly at guanine-rich promoter regions (3, 4) . 8-Oxoguanine DNA glycosylase 1 (OGG1) binds with high affinity to 8-oxoG in double-stranded DNA to initiate DNA base excision repair. In addition to this role, OGG1 has distinct signal transduction functions (5-7), interacts with 8-oxoG in gene regulatory regions, and facilitates gene expression (3, (7) (8) (9) (10) (11) (12) . These observations provide a potential explanation for the decreased inflammatory responses in Ogg1-deficient (Ogg1 −/− ) mice (13) (14) (15) (16) , which are otherwise viable and largely healthy (17) . Thus, we hypothesized that small-molecule OGG1 inhibitors may be clinically useful for the alleviation of inflammatory processes while still being well tolerated.
To screen for OGG1 inhibitors, we used a duplex oligonucleotide with the OGG1 substrate 8-oxo-7,8-dihydro-2′-deoxyadenosine and an excess of apurinic or apyrimidinic (AP) endonuclease 1 (APE1), which acts downstream of OGG1 and increases its turnover on damaged DNA (18) (Fig. 1, A and B) . We screened a library containing 17,940 (table S1) and identified a hit molecule with a median inhibitory concentration (IC 50 ) of 8.6 mM. During hit expansion, we developed TH5487 as a potent OGG1 inhibitor with an IC 50 of 342 nM, whereas structurally similar analogs TH2840 and TH5411 were inactive, with IC 50 values exceeding 100 mM (Fig. 1 , C and D, and figs. S1 to S3). This compound series was selective for OGG1; did not affect the activity of other DNA glycosylases (fig. S5A and table S2) or  various Nudix hydrolases and diphosphatases   (table S3); and did not intercalate DNA (fig.  S5B ). Previously, a hydrazide-based small molecule (O8) was reported to inhibit OGG1 with similar potency as TH5487 (19) . O8 was found to inhibit catalytic imine formation in OGG1 (19) , and we observed an increase in the potency of O8 by omitting APE1 from the reaction, in contrast to TH5487 (table S4) . APE1 readily released fluorescence from a natural AP site but only partially from an AP-site substrate preincubated with O8 ( fig. S5C ). Thus, TH5487 primarily inhibited the DNA glycosylase activity of OGG1, whereas O8 appeared to interfere with downstream b-lyase activity. To further validate OGG1 inhibition by TH5487, we performed electrophoretic mobility shift assays, where OGG1 bound to 8-oxoG:C-containing duplex oligonucleotide in a concentration-dependent manner ( fig. S4C ). The amount of OGG1-DNA complexes decreased in a dose-dependent manner upon addition of TH5487 (Fig. 1E) , demonstrating that TH5487 precludes OGG1 from binding oxidized DNA in vitro.
TH5487, but not the inactive analogs TH2840 and TH5411, increased the melting temperature for OGG1 in a concentration-dependent manner (Fig. 1F) . Thus, TH5487-mediated protein destabilization did not account for the observed decrease in enzyme activity, suggesting that TH5487 binds OGG1 similarly to 8-oxoG extruded from DNA. Supporting this, treatment with TH5487 resulted in a lower deuteration for all peptides forming the active site cavity (Fig. 1G and table  S5) . Thus, TH5487 is a potent and selective active site inhibitor that prevents OGG1 from binding to its DNA substrate.
To identify the precise binding site for this class of inhibitors, we determined the x-ray crystal structure of mouse OGG1 in complex with the more soluble analog TH5675 ( Fig. 1H; (20) . Notably, the Asp 322 side chain was within hydrogen-bond distance of the solvent accessible amine, which corresponds to the bromine atom in TH5487 ( fig. S6F ). These interactions were the result of a local conformational change in which the active site closed around the ligand ( fig. S6G and movie S1).
For OGG1 inhibitors to be pharmacologically useful, they need to engage and inhibit OGG1 in cells. TH5487 increased the melting temperature of OGG1 in human cells ( Fig. 2A) , demonstrating that TH5487 engaged its intended target in living cells and protected it from thermal denaturation. Furthermore, TH5487 impaired repair of genomic 8-oxoG induced by KBrO 3 . TH5487 caused a significant increase in genomic 8-oxoG after 2.5 hours (Fig. 2 , B and C), and at 24 hours, 50 ± 8% of the 8-oxoG remained in the TH5487-treated cells (Fig.  2C) , without disrupting proliferation ( fig. S7A) . Thus, genomic 8-oxoG and TH5487 were well tolerated by cells. Furthermore, the decrease in genomic 8-oxoG was a result of repair processes and not cellular replication. To further validate target engagement, we assessed the chromatin dynamics of OGG1-GFP (green fluorescent protein) fusion proteins. Cells were treated with KBrO 3 and released into medium containing TH5487 or dimethyl sulfoxide (DMSO). Consistent with previous reports (21), OGG1-GFP fusion proteins were immobilized at genomic DNA lesions introduced by KBrO 3 . Treatment with TH5487 increased the nuclear mobility of OGG1-GFP both 3 and 5 hours after KBrO 3 exposure (Fig. 2, D and E, and fig. S7 , B and C), suggesting that TH5487 prevented OGG1 binding to its genomic substrate in living cells.
OGG1 binds 8-oxoG at gene regulatory regions to mediate transcriptional activation in response to inflammatory stimuli (3, 7-11). In the absence of functional OGG1, a decreased inflammatory response is observed (3, (12) (13) (14) (15) (16) 22) . Because TH5487 prevents OGG1 from binding 8-oxoG in DNA, we examined if TH5487 could suppress proinflammatory gene expression. In line with previous observations (12) , human embryonic kidney (HEK) 293T cells lacking OGG1 displayed a reduced induction of CXCL1 [chemokine (C-X-C motif) ligand 1] mRNA after tumor necrosis factor-a (TNFa) stimulation ( Fig. 2F and fig. S7 , D and E). Treatment with 5 mM TH5487 decreased CXCL1 expression by >50% in wild-type but not in OGG1-knockout cells (Fig. 2F) . Thus, the compound may be used to specifically inhibit OGG1-dependent proinflammatory gene expression. Because respiratory epithelium is a key orchestrator of pulmonary innate immune responses (23), we stimulated a murine airway epithelial cell line (MLE 12) with TNFa (24) expression of an array of proinflammatory cytokines as well as C-C and C-X-C chemokines (Fig.  3, A to C, and fig. S8 ). Importantly, TH5487 decreased the expression of the same genes to near pretreatment levels (Fig. 3, C and E, and figs. S8 to S12). Inhibition was dose-dependent ( Fig. 3D  and fig. S10 ) and also observed with the potent inflammatory agent lipopolysaccharide (LPS) (25) (Fig. 3F and figs. S11 and S12). Crucially, TH5487 decreased TNFa-and LPS-induced gene expression in diploid human small-airway epithelial cells (hSAECs) as well (Fig. 3 , G to I, and figs. S9, S10, and S12). ROS generate a localized increase in OGG1 substrates in guanine-rich promoter regions (4, 6, 9, 10), including proinflammatory genes (3, 4, 12) . (3, (8) (9) (10) (11) , such as nuclear factor kB (NF-kB), which is the main driver of both TNFa-and LPS-induced proinflammatory gene expression (26) . Consistent with the observation that TH5487 prevents OGG1 from engaging damaged DNA in vitro and in cells (Figs. 1E and 2, D and E) , we observed that TH5487 decreased the recruitment of OGG1 to regulatory regions of proinflammatory cytokines in TNFa-challenged cells (Fig. 3J) . Consequently, binding of NF-kB to the same regulatory regions was significantly decreased by TH5487 in the chromatin of TNFa-exposed cells (Fig. 3K) and to its recognition sequence in nuclear extracts from mouse and human cells by TH5487 (Fig. 3L and  fig. S13, A to C) . In the presence of OGG1, TH5487 decreased NF-kB occupancy on 8-oxoG-containing DNA, whereas TH5487 alone was unable to inhibit NF-kB ( fig. S13, D and E) . Thus, TH5487 decreases proinflammatory gene expression by perturbing DNA occupancy of NF-kB and potentially other OGG1-dependent transacting factors (3, (8) (9) (10) (11) . TH5487 had no effect on the release of NF-kB from its inhibitory complex ( fig. S14 , A to C) but inhibited inflammatory gene expression similar to BMS-345541, an IkB kinase inhibitor (27) (fig.  S15A ). Thus, both TH5847 and BMS-345541 inhibit NF-kB function: TH5487 by preventing NF-kB binding to promoters (Fig. 3K ) and BMS-345541 by inhibiting NF-kB activation ( fig. S14 , A to C). This results in the same readout in the form of diminished induction of proinflammatory genes. The previously developed OGG1 inhibitor O8 (19) did not affect gene expression ( fig. S15A ), possibly because, in contrast to TH5487, it allows OGG1 binding to damaged DNA (19) (fig. S15 , B and C).
In addition, TH5487 is metabolically relatively stable and well tolerated in mice ( fig. S16A and tables S7 to S10). To assess whether TH5487 could down-regulate chemotactic (C-C and C-X-C) mediators (28) in vivo, we challenged mouse lungs with TNFa and profiled the gene expression of proinflammatory mediators. TNFa robustly induced the expression of pulmonary proinflammatory genes, but a prophylactic injection of TH5487 decreased the expression levels (Fig. 4,  A and B) . Challenge with TNFa or LPS induced the robust recruitment of neutrophils to the airways, which was decreased by up to 85 ± 5% by the prophylactic intraperitoneal administration of TH5487 (Fig. 4C and fig. S16 , B to G). We then administered TH5487 at different time points before or after challenge with TNFa and found that TH5487 reduced the pulmonary neutrophil count even when administered up to 9 hours after TNFa challenge ( Fig. 4D and fig. S17 ). Thus, TH5487 is efficacious in vivo, suggesting that the compound could be used for the treatment of inflammatory conditions. Finally, another potent and structurally Ten mM TH5487 increased the nuclear mobility of OGG1-GFP at 3 and 5 hours after KBrO 3 treatment. Quantifications of two (0-hour) or three (3-and 5-hour) independent experiments are shown. RFU, relative fluorescence units. (F) TH5487 inhibits TNFa-induced CXCL1 gene expression in wild-type, but not in OGG1-knockout (KO), HEK293T cells. Cells were treated with 0.05% DMSO or 5 mM TH5487 for 1 hour and TNFa (20 ng/ml) for 30 min. CXCL1 mRNA levels were determined with quantitative polymerase chain reaction (qPCR). Data are presented as averages ± SD from three independent experiments. For (B), (C), and (F), **P < 0.01, ***P < 0.001, ****P < 0.0001, and NS is not significant, using unpaired two-sided Student's t test.
distinct OGG1 inhibitor was recently published (29) . When tested, this compound had comparable anti-inflammatory effects ( fig. S18 ). Thus, we have developed a pharmacologically useful OGG1 inhibitor that is a potent and selective active site binder that prevents OGG1 from engaging damaged DNA in vitro and in cells, resulting in decreased proinflammatory gene expression by a mechanism that is distinct from other established therapeutic agents ( fig. S19 ). This is translated into a reduced neutrophil infiltration in mouse lungs challenged with TNFa or LPS, demonstrating that OGG1 inhibition may be a potentially useful strategy for the treatment of inflammation.
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4 of 6 and (G), decreasing concentrations of TH5487 were added before TNFa (20 ng/ml for 30 min). Changes in mRNA levels were determined by quantitative real-time PCR. Data are presented as averages ± SD from at least three independent experiments. (J) TH5487 decreases binding of OGG1 to promoters in chromatin.
(K) TH5487 perturbs DNA occupancy of NF-kB in chromatin. In (J) and (K), data are presented as averages ± SD from four independent experiments, and MLE 12 cells were treated with solvent or 5 mM TH5487 for 1 hour and exposed to TNFa (20 ng/ml) for 30 min. Chromatin was immunoprecipitated using antibody to epitope-tagged OGG1, or the p65 subunit of NF-kB. Fold changes in OGG1 and NF-kB binding to the indicated proximal promoter regions were determined by qPCR. (L) TH5487 perturbs binding of NF-kB to 8-oxoG-containing synthetic DNA in nuclear extracts from MLE 12 or hSAEC cells. p50-p65, heterodimer of NF-kB; p50-p50, homodimer of NF-kB. Images are representative of three independent experiments. In (D) to (I), *P < 0.05, **P < 0.01, ***P < 0.001, and NS is not significant, using unpaired two-sided Student's t test.
5 of 6 Target gene signals were normalized to housekeeping genes, and all data analyses were performed according to the manufacturer's instructions using their web-based software package (www.qiagen.com/us/shop/genes-and-pathways/data-analysiscenter-overview-page/) (n = 1 experiment). (C) Dose dependent inhibition of TNFa-induced neutrophil infiltration by TH5487. Mice (50% female and 50% male) were treated intraperitoneally with increasing doses of TH5487 and challenged intranasally with TNFa. Sixteen hours after challenge, mice were euthanized and lavaged. Neutrophil numbers in bronchoalveolar lavage fluid were determined in a blinded fashion. (D) TH5487 interrupts TNFa-induced ongoing inflammatory processes. Randomly selected groups of mice (50% female and 50% male) were challenged intranasally with vehicle or 20 ng TNFa per lung, with TH5487 administered intraperitoneally 1 hour before or 3, 6, or 9 hours thereafter. Sixteen hours after TNFa stimulation, mice were euthanized and lavaged.The levels of neutrophil infiltration were assessed as described for (C). In (C) and (D), ***P < 0.001, using unpaired two-sided Student's t test.
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